CHDI
Listed here are over 975 publications that describe some of the research funded (in whole or in part) by CHDI Foundation. You can also view just the subset of publications that have CHDI staff as authors.
Publication Search
Title
Journal
Covey DP, Dantrassy HM, Yohn SE, Castro A, Conn PJ, Mateo Y, Cheer JF
Inhibition of endocannabinoid degradation rectifies motivational and dopaminergic deficits in the Q175 mouse model of Huntington's disease
Shin B, Jung R, Oh H, Owens GE, Lee H, Kwak S, Lee R, Cotman SL, Lee JM, MacDonald ME, Song JJ, Vijayvargia R, Seong IS
Novel DNA aptamers that bind to mutant Huntingtin and modify its activity
Franich NR, Basso M, André EA, Ochaba J, Kumar A, Thein S, Fote G, Kachemov M, Lau AL, Yeung SY, Osmand A, Zeitlin SO, Ratan RR, Thompson LM, Steffan JS
Striatal mutant Huntingtin protein levels decline with age in homozygous Huntington's disease knock-in mouse models
J Huntingtons Dis
June 1, 2018
7 (2) :137-150
7 (2) :137-150
PMID: 29843246
PMCID: PMC6002862
DOI: 10.3233/JHD-170274
Suelves N, Miguez A, López-Benito S, Barriga GG, Giralt A, Alvarez-Periel E, Arévalo JC, Alberch J, Ginés S, Brito V
Early downregulation of p75(NTR) by genetic and pharmacological approaches delays the onset of motor deficits and striatal dysfunction in Huntington's disease mice
Martin DDO, Kay C, Collins JA, Nguyen YT, Slama RA, Hayden MR
A human huntingtin SNP alters post-translational modification and pathogenic proteolysis of the protein causing Huntington disease
Bertoglio D, Kosten L, Verhaeghe J, Thomae D, Wyffels L, Stroobants S, Wityak J, Dominguez C, Mrzljak L, Staelens S
Longitudinal characterization of mGluR5 using (11)C-ABP688 PET imaging in the Q175 mouse model of Huntington's disease
McClory H, Wang X, Sapp E, Gatune LW, Iuliano M, Wu CY, Nathwani G, Kegel-Gleason KB, DiFiglia M, Li X
The COOH-terminal domain of huntingtin interacts with RhoGEF kalirin and modulates cell survival
Schuldenzucker V, Schubert R, Muratori LM, Freisfeld F, Rieke L, Matheis T, Schramke S, Motlik J, Kemper N, Radespiel U, Reilmann R
Behavioral assessment of stress compensation in minipigs transgenic for the Huntington gene using cortisol levels: a proof-of-concept study
Chao MJ, Kim KH, Shin JW, Lucente D, Wheeler VC, Li H, Roach JC, Hood L, Wexler NS, Jardim LB, Holmans P, Jones L, Orth M, Kwak S, MacDonald ME, Gusella JF, Lee JM
Population-specific genetic modification of Huntington's disease in Venezuela
Mestre TA, Busse M, Davis AM, Quinn L, Rodrigues FB, Burgunder JM, Carlozzi NE, Walker F, Ho AK, Sampaio C, Goetz CG, Cubo E, Martinez-Martin P, Stebbins GT, Members of the MDS Committee on Rating Scales Development
Rating scales and performance-based measures for assessment of functional ability in Huntington's disease: critique and recommendations
Mov Disord Clin Pract
May 9, 2018
5 (4) :361-372
5 (4) :361-372
PMID: 30363510
PMCID: PMC6174516
DOI: 10.1002/mdc3.12617
Castro E, Polosecki P, Rish I, Pustina D, Warner JH, Wood A, Sampaio C, Cecchi GA
Baseline multimodal information predicts future motor impairment in premanifest Huntington's disease
Lee JK, Conrad A, Epping E, Mathews K, Magnotta V, Dawson JD, Nopoulos P
Effect of trinucleotide repeats in the Huntington's gene on intelligence
Pattamatta A, Cleary JD, Ranum LPW
All in the family: repeats and ALS/FTD
Gregory S, Crawford H, Seunarine K, Leavitt B, Durr A, Roos RAC, Scahill RI, Tabrizi SJ, Rees G, Langbehn D, Orth M
Natural biological variation of white matter microstructure is accentuated in Huntington's disease
Beckmann H, Bohlen S, Saft C, Hoffmann R, Gerss J, Muratori L, Ringelstein EB, Landwehrmeyer GB, Reilmann R
Objective assessment of gait and posture in premanifest and manifest Huntington disease - A multi-center study
Sun Z, Li Y, Ghosh S, Cheng Y, Mohan A, Sampaio C, Hu J
A data-driven method for generating robust symptom onset indicators in Huntington's disease registry data
Wijeratne PA, Young AL, Oxtoby NP, Marinescu RV, Firth NC, Johnson EB, Mohan A, Sampaio C, Scahill RI, Tabrizi SJ, Alexander DC
An image-based model of brain volume biomarker changes in Huntington's disease
Ann Clin Transl Neurol
April 2, 2018
5 (5) :570-582
5 (5) :570-582
PMID: 29761120
PMCID: PMC5945962
DOI: 10.1002/acn3.558
Reiner A, Deng YP
Disrupted striatal neuron inputs and outputs in Huntington's disease
CNS Neurosci Ther
April 2, 2018
24 (4) :250-280
24 (4) :250-280
PMID: 29582587
PMCID: PMC5875736
DOI: 10.1111/cns.12844
Carlozzi NE, Hahn EA, Goodnight SM, Kratz AL, Paulsen JS, Stout JC, Frank S, Miner JA, Cella D, Gershon RC, Schilling SG, Ready RE
Patient-reported outcome measures in Huntington disease: Quality of life in neurological disorders (Neuro-QoL) social functioning measures
Psychol Assess
April 2, 2018
30 (4) :450-458
30 (4) :450-458
PMID: 28557480
PMCID: PMC5708162
DOI: 10.1037/pas0000479
Lai JS, Goodnight S, Downing NR, Ready RE, Paulsen JS, Kratz AL, Stout JC, McCormack MK, Cella D, Ross C, Russell J, Carlozzi NE
Evaluating cognition in individuals with Huntington disease: Neuro-QoL cognitive functioning measures
Baake V, Coppen EM, van Duijn E, Dumas EM, van den Bogaard SJA, Scahill RI, Johnson H, Leavitt B, Durr A, Tabrizi SJ, Craufurd D, Roos RAC, Track-HD investigators
Apathy and atrophy of subcortical brain structures in Huntington's disease: A two-year follow-up study
Ament SA, Pearl JR, Cantle JP, Bragg RM, Skene PJ, Coffey SR, Bergey DE, Wheeler VC, MacDonald ME, Baliga NS, Rosinski J, Hood LE, Carroll JB, Price ND
Transcriptional regulatory networks underlying gene expression changes in Huntington's disease
Mestre TA, Carlozzi NE, Ho AK, Burgunder JM, Walker F, Davis AM, Busse M, Quinn L, Rodrigues FB, Sampaio C, Goetz CG, Cubo E, Martinez-Martin P, Stebbins GT, Members of the MDS Committee on Rating Scales Development|
Quality of life in Huntington's disease: Critique and recommendations for measures assessing patient health-related quality of life and caregiver quality of life
Bresciani A, Spiezia MC, Boggio R, Cariulo C, Nordheim A, Altobelli R, Kuhlbrodt K, Dominguez C, Munoz-Sanjuan I, Wityak J, Fodale V, Marchionini DM, Weiss A
Quantifying autophagy using novel LC3B and p62 TR-FRET assays
Ouk K, Aungier J, Cuesta M, Morton AJ
Chronic paroxetine treatment prevents disruption of methamphetamine-sensitive circadian oscillator in a transgenic mouse model of Huntington's disease
Minkova L, Gregory S, Scahill RI, Abdulkadir A, Kaller CP, Peter J, Long JD, Stout JC, Reilmann R, Roos RA, Durr A, Leavitt BR, Tabrizi SJ, Klöppel S, TRACK-HD Investigators
Cross-sectional and longitudinal voxel-based grey matter asymmetries in Huntington's disease
Espinoza FA, Turner JA, Vergara VM, Miller RL, Mennigen E, Liu J, Misiura MB, Ciarochi J, Johnson HJ, Long JD, Bockholt HJ, Magnota VA, Paulsen JS, Calhoun VD
Whole-brain connectivity in a large study of Huntington's disease gene mutation carriers and healthy controls
Lee CYD, Daggett A, Gu X, Jiang LL, Langfelder P, Li X, Wang N, Zhao Y, Park CS, Cooper Y, Ferando I, Mody I, Coppola G, Xu H, Yang XW
Elevated TREM2 gene dosage reprograms microglia responsivity and ameliorates pathological phenotypes in Alzheimer's disease models
Guo Q, Bin Huang, Cheng J, Seefelder M, Engler T, Pfeifer G, Oeckl P, Otto M, Moser F, Maurer M, Pautsch A, Baumeister W, Fernández-Busnadiego R, Kochanek S
The cryo-electron microscopy structure of huntingtin
Odish OFF, Reijntjes RHAM, van den Bogaard SJA, Roos RAC, Leemans A
Progressive microstructural changes of the occipital cortex in Huntington's disease
Kielar C, Morton AJ
Early neurodegeneration in R6/2 mice carrying the Huntington's disease mutation with a super-expanded CAG repeat, despite normal lifespan
Kovalenko M, Milnerwood A, Giordano J, St Claire J, Guide JR, Stromberg M, Gillis T, Sapp E, DiFiglia M, MacDonald ME, Carroll JB, Lee JM, Tappan S, Raymond L, Wheeler VC
HttQ111/+ Huntington's disease knock-in mice exhibit brain region-specific morphological changes and synaptic dysfunction
Pfister EL, DiNardo N, Mondo E, Borel F, Conroy F, Fraser C, Gernoux G, Han X, Hu D, Johnson E, Kennington L, Liu P, Reid SJ, Sapp E, Vodicka P, Kuchel T, Morton AJ, Howland D, Moser R, Sena-Esteves M, Gao G, Mueller C, DiFiglia M, Aronin N
Artificial miRNAs reduce Human Mutant Huntingtin throughout the striatum in a transgenic sheep model of Huntington's disease
Veldman MB, Yang XW
Molecular insights into cortico-striatal miscommunications in Huntington's disease
Davis MI, Crittenden JR, Feng AY, Kupferschmidt DA, Naydenov A, Stella N, Graybiel AM, Lovinger DM
The cannabinoid-1 receptor is abundantly expressed in striatal striosomes and striosome-dendron bouquets of the substantia nigra
Rebec GV
Corticostriatal network dysfunction in huntington's disease: Deficits in neural processing, glutamate transport, and ascorbate release
Sampaio C, Levey J, Klitzman R
Predictive testing and clinical trials in Huntington's disease: An ethical analysis
Mov Disord
February 20, 2018
33 (2) :243-247
33 (2) :243-247
PMID: 29205501
PMCID: PMC5854324
DOI: 10.1002/mds.27247
Mestre TA, Bachoud-Lévi AC, Marinus J, Stout JC, Paulsen JS, Como P, Duff K, Sampaio C, Goetz CG, Cubo E, Stebbins GT, Martinez-Martin P, Members of the MDS Committee on Rating Scales Development
Rating scales for cognition in Huntington's disease: Critique and recommendations
Hassler MR, Turanov AA, Alterman JF, Haraszti RA, Coles AH, Osborn MF, Echeverria D, Nikan M, Salomon WE, Roux L, Godinho BMDC, Davis SM, Morrissey DV, Zamore PD, Karumanchi SA, Moore MJ, Aronin N, Khvorova A
Comparison of partially and fully chemically-modified siRNA in conjugate-mediated delivery in vivo
Harrison DJ Roberton VH Vinh NN Brooks SP Dunnett SB Rosser AE
The effect of tissue preparation and donor age on striatal graft morphology in the mouse